Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis
Status:
Terminated
Trial end date:
2019-11-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that anti-IL-6 therapy is effective for
reducing plaque inflammation as measured by fluorine-2-deoxy-D-glucose positron emission
tomography (FDG-PET) in patients with rheumatoid arthritis (RA) who are synthetic
disease-modifying antirheumatic drugs (dMARD) inadequate responders and are naive to biologic
therapy.